EyePoint, Inc. (EYPT): who owns it and who trades it
As of Nov 16, 2026, EYPT insiders reported 10 open-market sales worth $2M and 2 purchases worth $72K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Cormorant Asset Management, LP (Other), with $942K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling EyePoint
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns EYPT
188 funds and institutions reported EYPT shares worth $1.3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Montanova Capital, LLC with 9.9%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Montanova Capital, LLC | 8.30M | 9.90% | $119M | No change |
| BlackRock, Inc. | 7.46M | 8.90% | $107M | +4% |
| Cormorant Asset Management, LP | 7.00M | 8.35% | $100M | -15% |
| Federated Hermes, Inc. | 5.68M | 6.78% | $81.2M | +0% |
| Adage Capital Partners Gp, L.l.c. | 4.83M | 5.76% | $69M | +46% |
| Franklin Resources Inc | 4.81M | 5.73% | $68.7M | -5% |
| Commodore Capital LP | 4.60M | 5.49% | $65.8M | +63% |
| Jupiter Topco LLC | 3.77M | 4.50% | $53.9M | – |
| Vanguard Capital Management LLC | 3.63M | 4.33% | $51.9M | +2% |
| Paradigm Biocapital Advisors LP | 2.89M | 3.45% | $41.3M | -8% |
| State Street Corp | 2.36M | 2.81% | $33.7M | +12% |
| Geode Capital Management, LLC | 2.06M | 2.46% | $29.5M | +4% |
| Aberdeen Group plc | 2.01M | 2.40% | $28.7M | +16% |
| Citadel Advisors LLC | 1.98M | 2.36% | $28.3M | +4% |
| Balyasny Asset Management L.P. | 1.81M | 2.16% | $25.9M | +26% |
| Parkman Healthcare Partners LLC | 1.29M | 1.54% | $18.4M | -5% |
| Eventide Asset Management, LLC | 1.25M | 1.49% | $17.8M | No change |
| Two Sigma Investments, LP | 1.18M | 1.41% | $16.9M | +174% |
| Essex Woodlands Management, Inc. | 1.08M | 1.29% | $15.5M | No change |
| Orbimed Advisors LLC | 1.07M | 1.28% | $15.3M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, EYPT insiders reported $72K of open-market purchases and $2M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Karen L. Zaderej | Director | Purchase | 10,600 | $4.93 | $52.3K | Form 4 |
| Jun 30, 2026 | Ramiro Ribeiro | Chief Medical Officer | Sale | 2,438 | $15.02 | $36.6K | Form 4 |
| Jun 30, 2026 | Ramiro Ribeiro | Chief Medical Officer | Sale | 2,437 | $15.00 | $36.6K | Form 4 |
| Apr 17, 2026 | Ramiro Ribeiro | Chief Medical Officer | Sale | 2,437 | $15.00 | $36.6K | Form 4 |
| Mar 16, 2026 | Jay S. Duker | CEO | Purchase | 1,500 | $13.15 | $19.7K | Form 4 |
| Mar 4, 2026 | Ramiro Ribeiro | Chief Medical Officer | Sale | 2,438 | $17.87 | $43.6K | Form 4 |
| Feb 17, 2026 | Ramiro Ribeiro | Chief Medical Officer | Sale | 2,437 | $15.00 | $36.6K | Form 4 |
| Jan 5, 2026 | Ramiro Ribeiro | Chief Medical Officer | Sale | 42,544 | $17.10 | $728K | Form 4 |
| Dec 4, 2025 | Cormorant Asset Management, LP +2 | Other | Sale | 60,000 | $15.70 | $942K | Form 4 |
| Dec 4, 2025 | Nancy Lurker | Director | Sale | 9,300 | $15.11 | $141K | Form 4 |
| Nov 28, 2025 | Nancy Lurker | Director | Sale | 500 | $14.95 | $7.5K | Form 4 |
| Nov 26, 2025 | Nancy Lurker | Director | Sale | 200 | $14.95 | $3K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Cormorant Asset Management, LP | Other | – | $942K | Dec 4, 2025 |
| Ramiro Ribeiro | Chief Medical Officer | – | $917K | Jun 30, 2026 |
| Nancy Lurker | Director | – | $151K | Dec 4, 2025 |
| Karen L. Zaderej | Director | $52.3K | – | Aug 18, 2026 |
| Jay S. Duker | President and CEO, Director | $19.7K | – | Mar 16, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
EYPT short interest
High short interest. 12.8% of EYPT shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went down 22%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 11.02M EYPT shares were sold short, 12.8% of the shares outstanding, down 48.2% from the report before. At the average daily volume of 29.80M shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 11.02M | 12.78% | -48% | 29.80M | 1.0 |
| Oct 15, 2026 | 21.26M | 24.66% | +2% | 2.63M | 8.1 |
| Sep 30, 2026 | 20.79M | 24.11% | +5% | 3.86M | 5.4 |
| Sep 15, 2026 | 19.81M | 22.98% | +9% | 3.08M | 6.4 |
| Aug 31, 2026 | 18.11M | 21.01% | -2% | 10.51M | 1.7 |
| Aug 14, 2026 | 18.43M | 21.37% | +2% | 2.02M | 9.1 |
| Jul 31, 2026 | 18.02M | 20.90% | +10% | 1.46M | 12.3 |
| Jul 15, 2026 | 16.43M | 19.59% | +9% | 1.59M | 10.3 |
| Jun 30, 2026 | 15.11M | 18.03% | +0% | 1.57M | 9.6 |
| Jun 15, 2026 | 15.08M | 17.98% | -0% | 1.09M | 13.8 |
| May 29, 2026 | 15.10M | 18.01% | +7% | 1.00M | 15.1 |
| May 15, 2026 | 14.15M | 16.88% | -0% | 838,595 | 16.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
EyePoint company events
EyePoint filed 17 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 19, 2026.
- Oct 19, 2026AnnouncementThe Company issued a press release announcing the Prioritization. Filing
- Oct 19, 2026AnnouncementEyePoint, Inc. issued a press release announcing topline data for LUCIA, one of its pivotal Phase 3 clinical trials evaluating DURAVYU™ for wet age-related macular degeneration (wet AMD). Filing
- Sep 10, 2026AnnouncementEyePoint, Inc. posted an updated investor presentation on its website at www.eyepoint.bio. Filing
- Aug 17, 2026AnnouncementEyePoint, Inc. issued a press release announcing topline data for LUGANO, one of its pivotal Phase 3 clinical trials evaluating DURAVYU™ for wet age-related macular degeneration (wet AMD). Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jul 30, 2026AnnouncementEyePoint, Inc. issued a press release announcing it has completed enrollment in the pivotal Phase 3 clinical trials evaluating DURAVYU™ for the treatment of diabetic macular edema. Filing
- Jul 17, 2026AgreementEyePoint, Inc. entered into a settlement agreement with the United States of America, acting through the U.S. Department of Justice and on behalf of the Office of Inspector General of the Department of Health and Human Services and the Defense Health Agency, acting on behalf of the TRICARE Program… Filing
- Jun 22, 2026LeadershipEyePoint, Inc. held its 2026 Annual Meeting of Stockholders on June 18, 2026 via live webcast. Filing
- May 14, 2026AnnouncementEyePoint, Inc. issued a press release announcing a positive recommendation from the independent Data Safety Monitoring Committee following completion of its third scheduled review of the Company’s ongoing pivotal Phase 3 program evaluating DURAVYU ™ for the treatment of wet age-related macular… Filing
- May 6, 2026ResultsReleased financial results. Filing
- Apr 13, 2026AnnouncementEyePoint, Inc. posted an updated investor presentation on its website at www.eyepoint.bio. Filing
- Mar 20, 2026AnnouncementShared information with investors. Filing
- Mar 4, 2026ResultsReleased financial results. Filing
- Mar 2, 2026AnnouncementEyePoint, Inc. issued a press release announcing the first patients dosed in both COMO and CAPRI, the Company's Phase 3 clinical trials of DURAVYU TM, formerly EYP-1901, for the treatment of diabetic macular edema. Filing
- Jan 7, 2026ResultsReleased financial results. Filing
- Dec 8, 2025RulesChanged its bylaws or articles. Filing
- Nov 19, 2025AnnouncementEyePoint Pharmaceuticals, Inc. issued a press release announcing a positive recommendation from the independent Data Safety Monitoring Committee following completion of its second scheduled review of the Company’s ongoing pivotal Phase 3 program evaluating DURAVYU ™ for the treatment of wet… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
EyePoint financials
Famous investors that hold EYPT
3 of the 50 well-known investors we track reported holding EYPT in their latest 13F filing. The largest position is Israel Englander's, worth $6.8M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 2.07M | $6.8M | 0.0% | +314% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.00M | $6.5M | 0.0% | +1% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 21,942 | $71.8K | 0.0% | +31% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 12 filings named EYPT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Commodore Capital LP | 13G/A | 0.0% |
| Nov 16, 2026 | Cormorant Asset Management, LP | 13G/A | 6.7% |
| Nov 16, 2026 | Cormorant Asset Management, LP | 13G/A | 6.7% |
| Nov 16, 2026 | Commodore Capital LP | 13G/A | 0.0% |
| Nov 4, 2026 | Federated Hermes, Inc. | 13G/A | 1.6% |
| Nov 4, 2026 | Federated Hermes, Inc. | 13G/A | 1.6% |
| Oct 30, 2026 | Vanguard Capital Management | 13G/A | 5.0% |
| Oct 30, 2026 | Vanguard Capital Management | 13G/A | 5.0% |
| Oct 27, 2026 | TANG CAPITAL MANAGEMENT, LLC | 13G | 9.6% |
| Oct 27, 2026 | TANG CAPITAL MANAGEMENT, LLC | 13G | 9.6% |
| Oct 7, 2026 | Federated Hermes, Inc. | 13G/A | 8.0% |
| Oct 7, 2026 | Federated Hermes, Inc. | 13G/A | 8.0% |
Questions about EyePoint, Inc. (EYPT) stock
Who owns the most EYPT stock?
The largest reported owner of EyePoint, Inc. (EYPT) is Montanova Capital, LLC, with 9.9% of the company. In total, 188 funds and institutions reported holding EYPT at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are EYPT insiders buying or selling?
In the last 12 months, EYPT insiders reported 2 open-market purchases worth $72K and 10 sales worth $2M. The latest trade was on Aug 18, 2026. See every trade.
What is the short interest in EYPT?
As of Oct 30, 2026, 11.02M EYPT shares were sold short, 12.8% of the shares outstanding, down 48.2% from the report before. At the average daily volume of 29.80M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold EYPT?
3 of the 50 well-known investors we track reported EYPT in their latest 13F filing, including Israel Englander, Ken Griffin, Paul Tudor Jones. The largest position is worth $6.8M. See all holders.
Executive pay
EyePoint's chief executive was paid a total of $5.6M for the year ended Dec 31, 2025. In the last 12 months, EyePoint's executives and directors bought $72K of stock on the open market and sold $1.1M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.